Vendor Risk Management for 340B Contract Pharmacy Administrators: HIPAA Compliance

Which vendors supporting 340B contract pharmacies may qualify as business associates?

A vendor may be a HIPAA business associate when it performs a service or function on behalf of a covered entity that involves creating, receiving, maintaining, or transmitting protected health information (PHI). The vendor’s title or its connection to the 340B Drug Pricing Program does not decide its status; what matters is the work it performs and the information it handles. See HHS’s Business Associates guidance.

Depending on their role and access, 340B administrators, claims processors, data-hosting providers, software vendors, billing or reconciliation services, and audit firms may qualify. A cloud provider can be a business associate when it stores or processes ePHI on a covered entity’s behalf, even if the information is encrypted and the provider cannot read it, as HHS explains in its cloud-service conduit guidance.

Do not assume every contract pharmacy is automatically a business associate—or that none can be one. Assess whether the pharmacy is performing a function on the covered entity’s behalf involving PHI, or acting in another capacity, and document the analysis. A pharmacy’s role under the 340B arrangement and its HIPAA role are related but distinct questions.

Also assess subcontractors. If a business associate engages a subcontractor that handles PHI on its behalf, the subcontractor generally must agree to the applicable HIPAA restrictions and safeguards. A vendor that does not meet the HIPAA business associate definition may still need appropriate confidentiality, security, and 340B contract protections.

What must a HIPAA business associate agreement cover?

When a vendor is a business associate, a written HIPAA business associate agreement (BAA) or other qualifying written arrangement must establish what the vendor may and must do with PHI. It must restrict uses and disclosures to those permitted by the agreement or required by law, and require appropriate safeguards—including applicable Security Rule protections for electronic PHI. HHS summarizes these required elements in its sample business associate agreement provisions.

The BAA must also address reporting impermissible uses or disclosures and breaches, cooperation with applicable individual rights requests, access to records for HHS oversight, protections for PHI handled by subcontractors, and return or destruction of PHI at termination when feasible. It must authorize termination for a material breach. Specify practical reporting timelines and escalation contacts so the covered entity can meet its own obligations.

For 340B operations, consider aligning the BAA with a separate services or contract pharmacy agreement. The BAA addresses PHI; the 340B agreement can define transaction-data access, reconciliation duties, record retention, audit cooperation, incident escalation, and corrective-action responsibilities. These operational details help translate protected health information safeguards into controls that support program oversight. A BAA does not by itself establish that the arrangement complies with 340B requirements.

How should covered entities define vendor roles and accountability?

Map the full workflow—from prescription and eligibility data through claims processing, replenishment, billing, reconciliation, and reporting—and identify which party handles each step. For each vendor, document what information it receives, the purpose of access, who can view or change records, and how the entity will obtain records needed to review transactions.

Clearly assign responsibility for 340B patient eligibility verification, accumulation and replenishment logic, Medicaid claim identification, duplicate discount prevention, exception handling, and maintenance of a complete 340B Drug Pricing Program audit trail. Define who reviews exceptions, who approves corrections, and how unresolved discrepancies reach the covered entity’s compliance lead.

Vendors can perform delegated tasks, but the covered entity remains responsible for ensuring its contract pharmacy arrangements meet 340B requirements. HRSA’s contract pharmacy services guidance describes covered entity responsibilities and the need to oversee these arrangements. Name accountable owners internally, maintain written policies, and avoid relying on a vendor’s general assurance of compliance as a substitute for entity oversight.

What should written contract pharmacy agreements address?

Before a contract pharmacy dispenses 340B drugs on the covered entity’s behalf, the arrangement must be documented and the pharmacy must be registered and active in 340B OPAIS. HRSA’s contract pharmacy guidance says written agreements should identify the relevant covered entity and pharmacy locations. HRSA also requires the covered entity to certify that a fully executed agreement is in effect when registering the arrangement; see the 340B OPAIS contract pharmacy instructions.

Use the agreement to specify which party purchases and maintains title to drugs, how dispensing and payment services operate, what records each party must create and retain, and how the covered entity can access data for review. Address eligibility and claims data, reconciliation, discrepancy resolution, audit cooperation, security and privacy duties, subcontracting, staff training, continuity of service, termination, and the return or secure disposition of records. Ensure the listed pharmacy locations match the registered arrangement.

Where PHI is involved and the pharmacy or another vendor qualifies as a business associate, include a BAA or incorporate compliant BAA terms in the written agreement. Review the agreement alongside applicable state pharmacy, Medicaid, and other requirements; contract language should match the actual data flows and operating model.

How can covered entities audit and monitor vendor performance?

Maintain written oversight procedures and records sufficient to show how the entity monitors its contract pharmacies and vendors. HRSA says covered entities must maintain auditable records and provide oversight; its contract pharmacy audit guidance recommends quarterly internal audits and annual independent audits, or more often when needed.

Use risk-based sampling to compare eligible prescriptions, dispensing records, purchasing and replenishment data, and payer claims. Test whether transactions are linked to the correct covered entity and pharmacy, whether exceptions are resolved and documented, and whether Medicaid billing identifiers agree with the entity’s current records. Reconcile dispensing, purchasing, and billing data rather than reviewing a vendor’s summary reports alone.

Track findings through documented corrective actions, assigned owners, and follow-up testing. Review vendor access controls, security incidents, subcontractors, and material system changes as part of ongoing monitoring. HRSA’s program integrity information describes audit reviews that may include policies, internal controls, Medicaid Exclusion File designations, and sampled 340B transactions. The entity should be able to produce a complete audit trail without depending on a vendor to reconstruct it after a request.

How should oversight address patient eligibility, diversion, and duplicate discounts?

Build eligibility checks into the process that determines whether a prescription may be attributed to 340B. Keep documentation that supports the patient’s relationship to the covered entity and the care provided, and make sure the eligibility logic reflects applicable HRSA guidance and the entity’s written policies. HRSA’s patient definition compliance resources explain that patient eligibility, diversion, and duplicate discounts are areas reviewed in 340B audits.

Prevent diversion by verifying that 340B drugs are dispensed only to eligible patients and for qualifying outpatient use. Prevent duplicate discounts by reconciling drug purchasing and claim data to ensure that a manufacturer’s 340B discount and a Medicaid rebate are not claimed for the same drug. Maintain exception reports and investigate mismatches, reversals, voids, and other adjustments.

Put these controls into written policies, train staff and vendors on their specific responsibilities, and periodically test whether the controls work in practice. The covered entity should retain access to the underlying records needed to demonstrate eligibility decisions, transaction flows, and corrective actions—not just a vendor’s final attestation.

What are the risks of dispensing 340B drugs to Medicaid fee-for-service patients?

Dispensing a 340B drug to a Medicaid fee-for-service patient is not categorically prohibited, but it requires controls to prevent a duplicate discount. A covered entity site must identify whether it will use 340B drugs for Medicaid fee-for-service patients (carve-in) or purchase drugs for those patients through other channels (carve-out). For carve-in billing, the site must report the relevant state and Medicaid billing number or NPI to HRSA so its information appears on the Medicaid Exclusion File. See HRSA’s Duplicate Discount Prohibition guidance.

Contract pharmacy Medicaid fee-for-service arrangements require particular care. HRSA’s Medicaid Exclusion File clarification describes the need for an arrangement among the covered entity, contract pharmacy, and state Medicaid agency to prevent duplicate discounts, and for the arrangement to be reported to HRSA. Confirm the current arrangement, billing identifiers, state requirements, and applicable HRSA records before claims are submitted.

Incorrect carve-in or carve-out status, mismatched identifiers, or incomplete claim reconciliation can create duplicate discount risk and undermine the entity’s audit trail. HRSA states that covered entities must maintain accurate records and prevent duplicate discounts; noncompliance may lead to repayment of discounts or removal from the program. Confirm the applicable billing setup with the state Medicaid agency and qualified compliance counsel when the facts or requirements are uncertain.

In short, effective vendor risk management combines a clear HIPAA business associate agreement when required, written allocation of 340B responsibilities, auditable transaction records, and recurring monitoring of eligibility, diversion, and Medicaid billing controls.

FAQs

When does a 340B administrator qualify as a HIPAA business associate?

A 340B administrator generally qualifies when it performs a function or service on behalf of a HIPAA covered entity that involves creating, receiving, maintaining, or transmitting PHI. Review its actual services and data access; the vendor label alone does not determine its status. HHS explains the definition in its Business Associates guidance.

Is a business associate agreement required if a vendor handles protected health information?

If the vendor is a business associate and handles PHI on behalf of a covered entity, the entity generally must have a compliant written BAA or other qualifying written arrangement before disclosing PHI. A limited exception may apply when the vendor is not a business associate under HIPAA, so assess the vendor’s role rather than relying only on whether it can see the data.

How often should covered entities audit contract pharmacy administration?

HRSA recommends quarterly internal audits and annual independent audits, or more frequently when necessary. Its contract pharmacy guidance also states that covered entities must provide oversight, conduct an independent audit at least once a year, and maintain records available for audit. See HRSA’s audit and compliance guidance.

Can a contract pharmacy dispense 340B drugs to Medicaid fee-for-service patients?

Yes, if the covered entity uses an applicable carve-in arrangement and the requirements to prevent duplicate discounts are met. The covered entity, pharmacy, and state Medicaid agency must have the relevant arrangement, and the covered entity must ensure its Medicaid billing information and HRSA records are accurate. Otherwise, the arrangement may need to carve out Medicaid fee-for-service claims.